News
The deadline for the Venture Challenge Fall 2023 edition is approaching fast!
Thursday 13 July at 14:00 CEST the call closes The Venture Challenge is a 10-week programme to develop an initial idea – a breakthrough research result – into a solid business case.
River BioMedics secures seed investment to progress its cardiovascular disease pipeline
Enschede, The Netherlands, 05 July 2023
STENTiT awarded with €12.5M funding from the European Innovation Council (EIC) Accelerator
The EIC funding comprises €2.5M of grants to conduct first clinical trials and up to €10M in follow-up equity investment to extend the trials and work on market introduction.
15 years of LifeSciences@Work event!
15 years of LifeSciences@Work and the Venture Challenge were celebrated last week at Pivot Park. There were multiple panel discussions, led by our amazing host for the day, Eline van Beest.
ExCulture wins Venture Challenge Spring 2023!
The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2023 spring edition is ExCulture! The innovative startup ExCulture has developed a proprietary, natural, mixed-culture fermentation bioprocess to produce the world’s most commonly used blood thinner, heparin.
LifeSciences@Work Succes Stories
Special Edition - 15-year anniversary
The consortium led by ParaMedir awarded €600,000 EFRO subsidy by SNN to develop solutions to improve outcome of acute heart failure patients.
Groningen – ParaMedir, an innovative medical technology company based in the Northern Netherlands, is proud to announce the significant EFRO subsidy of about €600,000.00 awarded by SNN (Samenwerkingsverband Noord-Nederland).
SeraNovo announces the closing of a multicompound deal with AstraZeneca
Leiden - Venture Challenge alumnus and winner SeraNovo announces a collaboration with AstraZeneca on multiple research projects. Source: Seranovo
Protinhi Therapeutics is awarded €7.5 Million by the EIC Accelerator program
• The funding will be dedicated to developing our broad-spectrum pan-flavi antiviral drug PTL244 to clinical phase II stage for the most common flavivirus: dengue. • Dengue is endemic in more than 100 countries (a.o.
These are the Venture Challenge Spring 2023 teams!
Six teams will start the Venture Challenge. Between 10 May and 29 June these starting lifesciences entrepreneurs will learn everything there is to know about setting up and pitching a businessplan.